A population-based study of the usefulness of screening for neuroblastoma

Lancet

Volumn 348, Issue 9043, 1996, Pages 1682-1687

  Woods, William G ^{a,b,c,d,e,f,g,h,i,j}   Tuchman, Mendel ^{a,b,c,d,e,f,g,h,i}   Robison, Leslie L ^{a,b,c,d,e,f,g,h,i}   Bernstein, Mark ^{a,b,c,d,e,f,g,h,i}   Leclerc, Jean Marie ^{a,b,c,d,e,f,g,h,i}   Brisson, Linda C ^{a,b,c,d,e,f,g,h,i}   Brossard, Josee ^{a,b,c,d,e,f,g,h,i}   Hill, Gerry ^{a,b,c,d,e,f,g,h,i}   Shuster, Jonathan ^{a,b,c,d,e,f,g,h,i}   Luepker, Russell ^{a,b,c,d,e,f,g,h,i}   Byrne, Timothy ^{a,b,c,d,e,f,g,h,i}   Weitzman, Sheila ^{a,b,c,d,e,f,g,h,i}   Bunin, Greta ^{a,b,c,d,e,f,g,h,i}   Lemieux, Bernard ^{a,b,c,d,e,f,g,h,i}  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^f Bureau of Chronic Epidemiology   (Canada)

^g University of Florida ^*  (United States)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j South Carolina Cancer Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HOMOVANILLIC ACID; VANILMANDELIC ACID;

ARTICLE; CANADA; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER SCREENING; CATECHOLAMINE METABOLISM; CATECHOLAMINE URINE LEVEL; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MASS SCREENING; NEUROBLASTOMA; PRIORITY JOURNAL; UNITED STATES; URINALYSIS;

EID: 0030597499     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)06020-5     Document Type: Article

References (29)

1. 1 Young JL, Ries LG, Silverberg E, et al. Cancer incidence, survival and mortality in children under 15 years of age. Cancer 1986; 58: 598-602.
2. 2 Bernstein ML, Leclerc JM, Bunin G, et al. A population-based study of neuroblastoma incidence, survival and mortality in North America. J Clin Oncol 1992; 10: 323-29.
3. 3 SawadaT, Nakata T, Takasugi N, et al. Mass screening for neuroblastoma in infants in Japan. Lancet 1984; ii: 271-73.
4. 4 Nishi M, Miyake H, Takeda T, et al. Effects of the mass screening of neuroblastoma in Sapporo City. Cancer 1987; 60: 433-36.
5. 5 Murphy SB, Cohn SL, Craft AW, et al. Do children benefit from mass screening for neuroblastoma? Consensus statement from the American Cancer Society Workshop on Neuroblastoma Screening. Lancet 1991; 337: 344-46.
6. 6 Woods WG. Screening for neuroblastoma in infants: more questions than answers. Screening 1992; 1: 273-79.
7. 7 Lemieux B, Auray-Blais C, Giguere R, Shapcott D, Tuchman M, Woods W. Quebec urinary screening program 1: a service to the population, 2: a new perspective. In: Therrell TL, ed. Advances in neonatal screening. Elsevier Science Publishers, 1987: 209-10.
8. 8 Tuchman M, Lemieux B, Auray-Blais C, et al. Screening for neuroblastoma at 3 weeks of age: methods and preliminary results from the Quebec Neuroblastoma Screening Project. Pediatrics 1990; 86: 765-73.
9. 9 Lemieux B, Auray-Blais C, Campion P, Giguere R. Thin layer chromatography of homovanillic and vanillylmandelic acids applicable to a large scale neuroblastoma screening program. In: Schmidt BJ, Diament AJ, Loghin-Grosso NS, eds. Current trends in infant screening. Amsterdam: Excerpta Medica, International Cong Ser 848. 1989: 401-05.
10. 10 Campion P, Dupuis DL. Neuroblastoma screening. Canadian Nurse 1991; 87: 17-19.
11. 11 Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993; 11: 1466-77.
12. 12 Bender A, MacDonald KL. The Minnesota Cancer Surveillance System: a summary of 1988 data. Minn Dept Health Disease Control Newsletter 1991; 19: 33-39.
13. 13 Greenberg MC, Greenberg C. The Report of the Provincial Pediatric Oncology Working Group. Toronto: Ontario Ministry of Health Publication, 1994.
14. 14 Kramer S, Meadows AT, Jarrett P, Evans AE. Incidence of childhood cancer: experience of a decade in a population-based registry. JN CI 1983; 70: 49-55.
15. 15 Gurney JC, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States: sex, race and 1-year age-specific rates by histologic type. Cancer 1995; 75: 2186-95.
16. 16 Vandenbroucke JB. A shortcut method for calculating 95% confidence interval of the standardized mortality ratio. Am J Epidemiol 1982; 115: 303-04.
17. 17 Stiller CA, Parkin DM. International variations in the incidence of neuroblastoma. Int J Cancer 1992; 52: 538-43.
18. 18 Philip T, Zucker JM, Bernard JL, et al. Improved survival at 2 and 5 years in the LMCE-1 unselected group of 72 children with stage 4 neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? J Clin Oncol 1991; 9: 1037-44.
19. 19 Woods WG, Lemieux B, Tuchman M. Neuroblastoma represents distinct clinical-biologic entities: a review and perspective from the Quebec Neuroblastoma Screening Project. Pediatrics 1992; 89: 114-18.
20. 20 Brodeur GM, Nakagawara A. Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hematol-Oncol 1992; 14: 111-16.
21. 21 Bessho F, Hashizume K, Nakajo T, Kamoshita S. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. J Pediatr 1991; 119: 237-41.
22. 22 Yamamoto K, Hayashi Y, Hanada R, et al. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. J Clin Oncol 1995; 13: 2033-38.
23. 23 Kaneko Y, Kanda N, Maseki N, et al. Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high risk neuroblastomas: a chromosome and N-myc amplification study. J Clin Oncol 1990; 8: 2005-13.
24. 24 Parker L. SENSE: Study for the Evaluation of Neuroblastoma Screening in Europe. Abstracts from the fourth international symposium on neuroblastoma screening. Stuttgart, 1995: 32.
25. 25 Kushner BH, LaQuaglia MP, Ambros PF, et al. Survival from locally invasive or metastatic neuroblastoma (NB) without cytotoxic therapy (RX). Proc Am Soc Clin Oncol 1993; 12: 413.
26. 26 Brodeur GM, Hayes FA, Green AA, et al. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from 60 individual patients. Cancer Res 1987; 47: 4248-53.
27. 27 Carlsen NLT. Epidemiological investigations on neuroblastomas in Denmark 1943-1980. Br J Cancer 1986; 54: 977-88.
28. 28 Draper GJ, Kroll ME, Stiller CA. Childhood cancer. In: Cancer surveys. Vol 19/20: trends in cancer incidence and mortality. London: Imperial Cancer Research Fund, 1994: 493-517.
29. 29 Esteve J, Parker L. Roy P, et al. Is neuroblastoma screening evaluation needed and feasible? Br J Cancer 1995; 71: 1125-31.